Evidence map›Paper›PMID 35872531›Full record

ArticleLung cancer (Amsterdam, Netherlands)2022

APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.

Vincent L Cannataro, Shalley Kudalkar, Krishna Dasari, Stephen G Gaffney, Heather M Lazowski, Laura K Jackson, Isil Yildiz, Rahul K Das, Bonnie E Gould Rothberg, Karen S Anderson and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Vincent L CannataroDepartment of Biology, Emmanuel College, Boston, MA, USA. Electronic address: cannatarov@emmanuel.edu.
Shalley KudalkarDepartment of Pharmacology, Yale University, New Haven, CT, USA.
Krishna DasariYale College, New Haven, CT, USA.
Stephen G GaffneyDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
Heather M LazowskiYale Cancer Center, Yale University, New Haven, CT, USA.
Laura K JacksonYale Cancer Center, Yale University, New Haven, CT, USA.
Isil YildizDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA; Department of Pathology, VACT Healthcare System, West Haven, CT, USA.
Rahul K DasYale Cancer Center, Yale University, New Haven, CT, USA.
Bonnie E Gould RothbergYale Cancer Center Innovations Laboratory, Yale Cancer Center, New Haven, CT, USA.
Karen S AndersonDepartment of Pharmacology, Yale University, New Haven, CT, USA; Yale Cancer Center, Yale University, New Haven, CT, USA; Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT, USA.
Jeffrey P TownsendDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA; Yale Cancer Center, Yale University, New Haven, CT, USA; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA; Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.
Yale University · USYale Cancer Center · USEmmanuel College - Massachusetts · US

Funding

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Roy S Herbst · 2015 to 2026
$31.1M
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck CancerP50DE030707 · NIDCR · YALE UNIVERSITY · PI BURTNESS, BARBARA · 2020 to 2024
$11.8M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancerR01DE027942 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANDERSON, KAREN S., ISSAEVA, NATALIA · 2019 to 2023
$2.1M
Bioinformatics of metastatic migration historiesR01LM013385 · NLM · TEMPLE UNIV OF THE COMMONWEALTH · PI KUMAR, SUDHIR · 2020 to 2023
$1.4M
Prognostic markers in metastatic melanomaK08CA151645 · NCI · YALE UNIVERSITY · PI GOULD ROTHBERG, BONNIE ELYSSA · 2010 to 2014
$527k
NCI NIH HHS K08 CA151645NCI NIH HHS P50 CA196530NCI NIH HHS T32 CA193200NIDCR NIH HHS P50 DE030707NIDCR NIH HHS R01 DE027942NLM NIH HHS R01 LM013385
6 · The paper itself

Abstract

Lung squamous-cell carcinoma originates as a consequence of oncogenic molecular variants arising from diverse mutagenic processes such as tobacco, defective homologous recombination, aging, and cytidine deamination by APOBEC proteins. Only some of the many variants generated by these processes actually contribute to tumorigenesis. Therefore, molecular investigation of mutagenic processes such as cytidine deamination by APOBEC should also determine whether the mutations produced by these processes contribute substantially to the growth and survival of cancer. Here, we determine the processes that gave rise to mutations of 681 lung squamous-cell carcinomas, and quantify the probability that each mutation was the product of each process. We then calculate the contribution of each mutation to increases in cellular proliferation and survival. We performed in vitro experiments to determine cytidine deamination activity of APOBEC3B against oligonucleotides corresponding with genomic sequences that give rise to variants of high cancer effect size. The largest APOBEC-related cancer effects are attributable to mutations in PIK3CA and NFE2L2. We demonstrate that APOBEC effectively deaminates NFE2L2 at the locations that confer high cancer effect. Overall, we demonstrate that APOBEC activity can lead to mutations in NFE2L2 that have large contributions to cancer cell growth and survival, and that NFE2L2 is an attractive potential target for therapeutic intervention.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsCarcinogenesisCarcinoma, Non-Small-Cell LungCytidineCytidine DeaminaseHumansLungMinor Histocompatibility AntigensMutagenesisMutationNF-E2-Related Factor 2APOBEC3B protein, humanCytidineCytidine DeaminaseMinor Histocompatibility AntigensNFE2L2 protein, humanNF-E2-Related Factor 2APOBECCancer evolutionMolecular epidemiologyMolecular signaturesNFE2L2

Identifiers

PMID35872531
PMCPMC10126952
OpenAlexW4284977493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.